Is Medical Research Informing Professional Practice More Highly Cited? Evidence from AHFS DI Essentials in Drugs.com by Thelwall, Mike et al.
Is Medical Research Informing Professional Practice More Highly Cited? 
Evidence from AHFS DI Essentials in Drugs.com1 
Mike Thelwall, Kayvan Kousha, Mahshid Abdoli  
Statistical Cybermetrics Research Group, School of Mathematics and Computer Science, 
University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, UK. 
 
Citation-based indicators are often used to help evaluate the impact of published medical 
studies, even though the research has the ultimate goal of improving human wellbeing. One 
direct way of influencing health outcomes is by guiding physicians and other medical 
professionals about which drugs to prescribe. A high profile source of this guidance is the 
AHFS DI Essentials product of the American Society of Health-System Pharmacists, which 
gives systematic information for drug prescribers. AHFS DI Essentials documents, which are 
also indexed by Drugs.com, include references to academic studies and the referenced work 
is therefore helping patients by guiding drug prescribing. This article extracts AHFS DI 
Essentials documents from Drugs.com and assesses whether articles referenced in these 
information sheets have their value recognised by higher Scopus citation counts. A 
comparison of mean log-transformed citation counts between articles that are and are not 
referenced in AHFS DI Essentials shows that AHFS DI Essentials references are more highly 
cited than average for the publishing journal. This suggests that medical research  
influencing drug prescribing is more cited than average. 
Introduction 
Citation counts are important in medical fields to help research evaluation. In the UK 
Research Excellence Framework (REF) 2014, although only 11 of the 36 disciplinary areas 
into which all research was categorised drew upon citation counts, these 11 included Clinical 
Medicine and the two other health fields (Wilsdon, Allen, Belfiore, Campbell, Curry, et al. 
2015). Citations counts and related indicators, such as Journal Impact Factors and the h-
index, may also be used in appointments, promotion, tenure and funding decisions (e.g., 
Curry, 2012; Feder & Madara, 2008), although various bodies have outlawed some or all of 
these (Schekman & Patterson, 2013). Citation counts have well-known limitations because 
they do not directly measure research value. In particular, applied research can be useful for 
non-academics that do not cite it and so can be undervalued by traditional citation counts 
(e.g., biomedical research: Lewison, & Dawson, 1998). It is therefore important to seek 
other indicators for different types of research value (Priem, Taraborelli, Groth, & Neylon, 
2010) including in the medical sciences (Barbic, Tubman, Lam, & Barbic, 2016; Scarlat, 
Mavrogenis, Pećina, & Niculescu, M, 2015). One way in which medical research can be 
useful is by influencing medicine prescribing by clinicians. Although previous studies have 
shown that it is possible to get evidence of clinical impact from citations in UK health 
professional guidelines (Grant, 1999; Grant, Cottrell, Cluzeau, & Fawcett, 2000; Kryl, Allen, 
Dolby, Sherbon, & Viney, 2012; Lewison & Sullivan, 2008; Thelwall & Maflahi, 2016) and 
indirectly from mainly U.S.-based clinical trials (Thelwall & Kousha, 2016), additional sources 
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of evidence are needed for a more complete picture, including for the key step of drug 
prescribing.  
 In the biomedical field, citations in various forms are widely used in research 
evaluation. These include simple citation counts, Journal Impact Factors (JIFs) and the h-
index, despite the acknowledged limitations of all of these. The importance of using some 
form of citation analysis for biomedical research has been implicitly acknowledge by the 
creation of a new indicator, The Relative Citation Ratio (RCR), by the Office of Portfolio 
Analysis, National Institutes of Health (Hutchins, Yuan, Anderson, Santangelo, 2016). The 
purpose of the RCR was to overcome many of the limitations of other indicators through the 
use of a complex algorithm to minimise the risk that articles are unfairly treated in citation 
comparisons. Nevertheless, citation-based algorithms cannot measure the clinical value of 
research. It role is to support rather than replace expert judgements. 
The American Society of Health-System Pharmacists (ASHP) is a professional 
association to provide support for, and advocacy on behalf of, pharmacists in hospitals and 
other parts of the health system in the U.S.A. It that produces, amongst other things, “an 
evidence-based foundation for safe and effective drug therapy” 
(www.ashp.org/menu/AboutUs/WhatWeDo). Its key product for practitioners is AHFS DI 
Essentials, which gives a range of information about drugs to inform decisions about 
whether to prescribe them and how to identify problems with patients taking them. This 
appears to be an independent evidence-based source of drug information because ASHP 
publishes clear guidelines for this (http://www.ahfsdruginformation.com/editorial-
independence/). Each medication has a self-contained document (called a monograph) that 
is underpinned by traditional academic references through a reference list at the end. The 
documents are intended to support prescribing in the U.S.A. but, through their hosting on 
the website drugs.com, also reach an international audience. Drugs.com was the most 
popular pharmacy website in the world, according to Alexa.com in December 2016 
(http://www.alexa.com/topsites/category/Top/Health/Pharmacy), with half (48.5%) of its 
visitors originating from the U.S.A., but India, the UK, Canada and Australia also having 
substantial numbers of users (http://www.alexa.com/siteinfo/drugs.com). 
Because of its authoritative origins and the presence of references, AHFS DI 
Essentials is a suitable new source of evidence about scholarly articles that have had an 
impact on prescribing practices. In contrast to the free online UK NICE Guidelines (Thelwall 
& Maflahi, 2016), it focuses on drugs rather than illnesses, and is not an official national 
source of information. Nevertheless, its extensive and focused collection of medical 
references is potentially useful as applied medical impact evidence. There are other similar 
national sources of drug information, such as the British National Formulary (BNF) 
pharmaceutical reference book from the UK’s Royal Pharmaceutical Society and British 
Medical Association, and Martindale: The Complete Drug Reference from the UK’s Royal 
Pharmaceutical Society publishing house, but AHFS DI Essentials seems to be authoritative 
and one of the few that is free online. 
Research questions 
Articles referenced in AHFS DI Essentials apparently have a direct impact on prescribing 
practice in the U.S.A. and therefore successfully achieve the main goal of medical research: 
improving health outcomes. Nevertheless, the authors of the referenced articles are likely to 
be evaluated by the publishing venue (the perceived value of the journal) or their citation 
counts in the form of a h-index or a total citation count. If articles referenced in AHFS DI 
Essentials tend not to be highly cited, then the contributions of their authors would be 
undervalued in research evaluations. This is possible because basic medical research attracts 
citations from both basic and applied research, whereas applied research attracts few basic 
citations in medicine (Narin, Pinski, & Gee, 1976). Hence the main research question is to 
check whether the traditional research evaluation source of quantitative evidence, 
academic citations, undervalues AHFS DI Essentials references. 
 Are articles referenced in AHFS DI Essentials less cited than average? 
Methods 
The overall research design was to extract all references from AHFS DI Essentials, identify 
the most cited journals, and compare the citation counts of the AHFS DI Essentials 
references in these journals with the remaining articles to see if they tend to be more cited. 
Although a more standard approach would be to compare papers within individual Scopus 
or Web of Science fields rather than within individual journals, a journal-based approach is 
preferable for greater specificity. In particular, several important medical journals are 
generalist (e.g., NEJM, Lancet, JAMA) and therefore not amenable to fine-grained field 
categorisation. In contrast, a focus on journals allows the finest grained classification 
possible (at least for any journal-based classification scheme, c.f.: Small, Sweeney, & 
Greenlee, 1985) without the possibility that the results are tainted by inappropriate or 
multiple journal classifications. Another advantage is that medical professionals may focus 
on specific high impact journals (as claimed by: Goldacre, 2009), which may distort the 
relationship between the value of an article and the number of times it is cited, undermining 
field-wide analyses. Two disadvantages of a focus on journals are reduced statistical power 
from fewer articles to analyse in each individual test and reduced statistical power from 
losing the differentiation between higher and lower average quality journals in the same 
field. Moreover, industry-funded research may tend to be published in higher impact, more 
general journals (Jefferson, Di Pietrantonj, Debalini, Rivetti, & Demicheli, 2009b) which will 
affect the results to some extent, although this would also be true for a field-based 
classification scheme if industry articles received a citation boost from their presence in 
higher impact journals. 
 Although AHFS DI Essentials references include books, reviews, meta-analyses, and 
other documents the analysis here focuses on standard journal articles because these are 
the primary vehicle for publishing original research and therefore the most important type 
of cited document from a research evaluation perspective. 
The AHFS DI Essentials documents are not publically available from the originating 
organisation’s website and so they were accessed from Drugs.com instead. The Drugs.com 
sitemap (https://www.drugs.com/sitemap_index.xml.gz) was used to identify the 2417 
AHFS DI Essentials pages in the site (with URLs starting with 
https://www.drugs.com/monograph/) and these were downloaded using the free web 
crawler SocSciBot (socscibot.wlv.ac.uk) on 21 October 2016, using a slow ethical crawl 
(Thelwall & Stuart, 2006). The references on these pages were extracted using a program 
added to the free software Webometric Analyst (lexiurl.wlv.ac.uk: Drugs.com: Extract 
references in the Services menu). The metadata from articles in the ten most cited journals 
identified in the reference lists was then downloaded from the Scopus website in November 
2016, covering the 21 years from 1996 (when Scopus expanded its coverage) to 2016. Only 
documents of Scopus type Journal Article, excluding reviews, were downloaded. One of the 
journals, Drugs, had few articles in recent years (most were classified by Scopus as other 
document types) and so the 11th journal largest was also downloaded as an addition. Scopus 
was chosen in preference to the Web of Science for its greater coverage of the literature, 
with the latter essentially forming a subset of the former (Archambault, Campbell, Gingras, 
& Larivière, 2009; Moed & Visser, 2008). 
The next stage was to match the AHFS DI Essentials references with the Scopus 
articles for the 11 journals. Although the AHFS DI Essentials references were reasonably 
standardised, they did not include DOIs, used abbreviated journal names and included many 
nonstandard documents, making the matching process not straightforward. To ensure 
accuracy, articles were matched based on PubMed IDs, ignoring articles in AHFS DI 
Essentials and Scopus without PubMed IDs. Thus, for each journal, two lists of articles were 
created: one with PubMed IDs and matching a AHFS DI Essentials PubMed ID, and one with 
PubMed IDs but no matching AHFS DI Essentials PubMed ID. Articles from journals in years 
with no AHFS DI Essentials references were discarded as unnecessary for the subsequent 
indicator calculations. 
For each journal, the year-normalised average citation count of articles referenced 
by AHFS DI Essentials was calculated by comparing it to the remaining articles in the journal. 
The Mean Normalised Log Citation Score (MNLCS) was used for this (Thelwall, 2017). This 
calculation is appropriate for individual academic journals because their citations tend to be 
highly skewed (de Solla Price, 1976), following hooked power law distribution (Thelwall, 
2016a) and the MNLCS incorporates a logarithmic transformation to eliminate this skewing. 
MNLCS is preferable to MNCS (Waltman, van Eck, van Leeuwen, Visser, & van Raan, 2011ab) 
because of the skewed nature of citation counts, an issue that is also not dealt with by the 
Relative Citation Ratio (RCR) (Hutchins, Yuan, Anderson, Santangelo, 2016). 
For each AHFS DI Essentials article 𝑑, its citation count 𝑐𝑑 is replaced by 𝑙𝑛(1 +
𝑐𝑑)/𝑦(𝑐𝑑) where 𝑦(𝑐𝑑) is the arithmetic mean of the 𝑙𝑛(1 + 𝑐)  values for all articles 
published in the same journal and year as 𝑑, excluding the matching AHFS DI Essentials 
articles (to increase statistical power). The MNLCS value for the journal is then the 
arithmetic mean of all the adjusted citation counts 𝑙𝑛(1 + 𝑐𝑑)/𝑦(𝑐𝑑). This calculation is not 
biased against newer articles because the citation count of each article is normalised against 
other articles from the same year. Although this gives an advantage to articles published 
earlier in the year, this should not introduce a source of systematic bias for or against AHFS 
DI Essentials references. Confidence intervals were calculated using Fieller’s (1954) formula 
for the ratio of two normal distributions, which is a conservative approach because it treats 
the journal citation average as an estimate rather than a precise value (see also: Thelwall, 
2017, in press). 
Results 
For each journal, the year-normalised average number of citations per article is higher than 
the journal average, and the difference is statistically significant in all cases (Table 1). 
Surprisingly, the highest impact general medical journals are at the top of the list and the 
difference between individual journals is statistically significant for the top journals (as a 
rule of thumb, if the confidence intervals do not overlap or only overlap a little then the 
difference is statistically significant). Additional investigations, as described below, were 
conducted to explore and check the results. 
 
  
Table 1. Year-normalised average log citations (MNLCS) for articles referenced by AHFS DI 
Essentials references for the 11 journals with the most articles. Journals are ordered by 
MNLCS. 
Journal 
AHFS-
cited 
articles MNLCS (95% CI) 
Journal 
articles 
First 
year 
Last 
year Years 
The Lancet 336 1.89 (1.84,1.94) 11749 1996 2015 20 
JAMA 171 1.58 (1.51, 1.65) 5897 1996 2016 19 
New England Journal of Medicine 613 1.47 (1.45, 1.49) 6064 1996 2015 20 
Circulation 114 1.36 (1.32, 1.41) 14270 1996 2015 20 
BMJ 36 1.36 (1.23, 1.48) 5230 1996 2012 16 
Journal of Clinical Oncology 377 1.31 (1.29, 1.34) 10360 1996 2015 20 
Clinical Infectious Diseases 201 1.29 (1.25, 1.33) 8307 1996 2016 21 
Archives of Internal Medicine/ 
JAMA Internal Medicine 50 1.19 (1.12, 1.25) 3542 1996 2013 13 
Antimicrobial Agents & 
Chemotherapy 364 1.18 (1.15, 1.21) 13533 1996 2015 20 
Pediatrics 54 1.16 (1.08, 1.23) 7022 1996 2015 16 
Drugs 56 1.12 (1.05, 1.19) 417 1996 2015 12 
 
Despite the overall average citation advantage, individual articles referenced by AHFS DI 
Essentials may still be less cited than average for the publishing journal. For example, 14 of 
the 336 in the top journal in Table 1, The Lancet, had below average citation counts. An 
examination of these found many that were not standard research articles (Table 2), 
explaining this. Nevertheless, the prevalence of non-articles within the Lancet Scopus results 
suggests that the high MNLCS values for AHFS-cited articles in The Lancet in Table 1 may be 
at least partly due to the presence of non-article document types classified as articles in 
Scopus within the remainder of the journal (additional manual checks found similar 
classification errors in some of the remaining articles in this journal). Similar problems 
occurred in eight of the remaining ten journals (see Appendix and Table 3). 
  
Table 2. All articles referenced by AHFS DI Essentials but attracting fewer citations than 
average for The Lancet. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in journal 
website 
1998 0 0.00 
WHO launches cautiously optimistic report on 
health 
News 
2008 2 0.36 
Timeframe for thrombolysis in acute ischaemic 
stroke 
Comment 
1996 4 0.54 Treatment of Kawasaki disease Commentary 
1997 8 0.68 
Acute pancreatitis during treatment with 
amiodarone 
Research Letter 
1999 12 0.83 Hypercalcaemia in sarcoidosis Case Report 
1998 9 0.84 Raloxifene-associated hepatitis Research Letter 
1998 10 0.87 Experts argue about tamoxifen prevention trial News 
1997 16 0.88 
Aberrant atrioventricular conduction triggered by 
antimalarial prophylaxis with mefloquine 
Research Letter 
2011 33 0.90 Spider bite Seminar 
1997 19 0.93 
Fatal toxic epidermal necrolysis associated with 
mefloquine antimalarial prophylaxis 
Research Letter 
2000 19 0.96 
Pharmacological implications of lengthened in-
utero exposure to nevirapine 
Research Letter 
2005 33 0.99 
Single-dose ciprofloxacin versus 12-dose 
erythromycin for childhood cholera: A randomised 
controlled trial 
Article 
2010 23 0.99 
Alteplase for ischaemic stroke-much sooner is 
much better 
Comment 
2012 60 0.99 
Efficacy and safety of an extended nevirapine 
regimen in infant children of breastfeeding 
mothers with HIV-1 infection for prevention 
Article 
 
The second journal in Table, 1, JAMA, also has papers classified as articles in Scopus that are 
classified as something else in the JAMA website (Table 3). In addition, some JAMA papers 
that were classified as articles in Scopus and in the JAMA website were not classical journal 
articles. For example, Typhoid fever (http://jamanetwork.com/journals/jama/article-
abstract/418141) has a subtitle Case Presentation and starts, “A 35-year-old Maryland woman came 
to her local hospital on December 4, 1994, complaining of fever and chills for 1 week.” This is clearly 
not a traditional medical journal article. Similarly, the two different articles with the same title, 
“From the Food and Drug Administration” (http://jamanetwork.com/journals/jama/article-
abstract/418112 and http://jamanetwork.com/journals/jama/article-abstract/415730) are news 
stories even though they are both labelled “Article” by JAMA and Scopus. The first one has subtitle 
State Contracts for Enforcement of FDA Tobacco Regulations and starts, “The FDA is contracting with 
states throughout the country to help enforce requirements of the new tobacco regulation to 
protect children and adolescents.” Hence the problem here is the non-standard labelling of outputs 
by JAMA and copying by Scopus. 
  
Table 3. All articles referenced by AHFS DI Essentials but attracting fewer citations than 
average for JAMA. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in journal 
website 
1997 0 0.00 From the Food and Drug Administration. Article  
1997 1 0.21 From the Food and Drug Administration. Article  
2005 37 0.71 
Life-threatening sepsis associated with 
adjuvant doxorubicin plus docetaxel for 
intermediate-risk breast cancer 
Brief Report 
2008 42 0.76 
Comparison of annual and biannual mass 
antibiotic administration for elimination of 
infectious trachoma 
Article 
2005 55 0.78 
Multidrug resistance among persons with 
tuberculosis in California, 1994-2003 
Article 
2007 60 0.81 Adult cystic fibrosis 
Grand Rounds/   
| Clinician's 
Corner 
2006 71 0.81 
Effect of a single mass antibiotic distribution 
on the prevalence of infectious trachoma 
Article 
2006 77 0.83 
Botulism in 4 adults following cosmetic 
injections with an unlicensed, highly 
concentrated botulinum preparation 
Brief Report  
2004 81 0.85 
Growth hormone - Releasing hormone in HIV-
infected men with lipodystrophy: A 
randomized controlled trial 
Preliminary 
Communication  
2010 55 0.85 
Atypical fractures as a potential complication 
of long-term bisphosphonate therapy 
Grand Rounds/ 
Clinician's 
Corner 
1997 16 0.86 Typhoid fever Article 
1996 17 0.88 
Importance of Surrogate Markers in 
Evaluation of Antiviral Therapy for HIV 
Infection 
Article 
1996 23 0.97 
Antibody response to measles-mumps-rubella 
vaccine of children with mild illness at the 
time of vaccination 
Article 
 
2008 124 0.98 
Sildenafil treatment of women with 
antidepressant-associated sexual dysfunction: 
A randomized controlled trial 
Article 
 
Antimicrobial Agents & Chemotherapy (Table 4) and the Journal of Clinical Oncology (Table 
5) do not seem to have non-standard article types classified as articles in Scopus, as 
confirmed by additional random checks on low cited articles. Thus, these journals give the 
clearest evidence that articles referenced by AHFS DI Essentials are more highly cited than 
comparable articles from the same journal. The list sin Tables 4 and 5 also gives concrete 
evidence that articles useful enough to be references in AHFS DI Essentials do not 
necessarily attract many Scopus citations.  
 
  
Table 4. Top 20 articles referenced by AHFS DI Essentials but attracting fewer citations than 
average for Journal of Clinical Oncology. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in 
journal 
website 
2002 17 0.64 
Phase I clinical and pharmacologic trial of intravenous 
estramustine phosphate 
Article 
1998 19 0.68 
Combination of consecutive low-dose cisplatin with 
bleomycin, vincristine, and mitomycin for recurrent cervical 
carcinoma 
Article 
2008 17 0.71 
Fatal toxic epidermal necrolysis associated with cetuximab 
in a patient with colon cancer 
Article 
1998 28 0.76 
Phase III randomized trial comparing cisplatin and 
carboplatin with or without ifosfamide in patients with 
advanced non-small-cell lung cancer 
Article 
1998 32 0.79 
Ninety-six-hour infusional paclitaxel as salvage therapy of 
ovarian cancer patients previously failing treatment with 3-
hour or 24-hour paclitaxel infusion regimens 
Article 
1996 32 0.79 
Paclitaxel in combination chemotherapy with radiotherapy 
in patients with unresectable stage III non-small-cell lung 
cancer 
Article 
2005 34 0.81 
Study of paclitaxel, etoposide, and cisplatin chemotherapy 
combined with twice-daily thoracic radiotherapy for 
patients with limited-stage small-cell lung cancer: A 
Radiation Therapy Oncology Group 9609 phase II study 
Article 
2005 35 0.82 
Side effects related to cancer treatment: Case 2. Splenic 
rupture following pegfilgrastim 
Article 
1996 38 0.83 
Phase I and pharmacologic study of high doses of the 
topoisomerase I inhibitor topotecan with granulocyte 
colony-stimulating factor in patients with solid tumors 
Article 
1998 42 0.85 
Phase II study of carmustine, dacarbazine, cisplatin, and 
tamoxifen in advanced melanoma: A southwest oncology 
group study 
Article 
1997 37 0.86 
Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in 
comparison to cisplatin plus cyclophosphamide in patients 
with epithelial ovarian cancer 
Article 
2000 44 0.86 
Phase I and pharmacokinetic study of a new taxoid, RPR 
109881A, given as a 1-hour intravenous infusion in patients 
with advanced solid tumors 
Article 
1997 38 0.86 
Fluorouracil plus racemic leucovorin versus fluorouracil 
combined with the pure l-isomer of leucovorin for the 
treatment of advanced colorectal cancer: A randomized 
phase III study 
Article 
1997 41 0.88 
Prospectively randomized north central cancer treatment 
group trial of intensive-course fluorouracil combined with 
the l-isomer of intravenous leucovorin, oral leucovorin, or 
intravenous leucovorin for the treatment of advanced 
colorectal cancer 
Article 
1997 41 0.88 
Phase II randomized trial of gallium nitrate plus fluorouracil 
versus methotrexate, vinblastine, doxorubicin, and cisplatin 
in patients with advanced transitional-cell carcinoma 
Article 
1999 47 0.88 
Cisplatin, etoposide, and paclitaxel in the treatment of 
patients with extensive small-cell lung carcinoma 
Article 
2007 36 0.88 Bevacizumab 5 mg/kg can be infused safely over 10 minutes Article 
1997 45 0.90 
Rapid recovery of spermatogenesis after mitoxantrone, 
vincristine, vinblastine, and prednisone chemotherapy for 
Hodgkin's disease 
Article 
1999 56 0.92 
Phase I and pharmacologic study of the tyrosine kinase 
inhibitor SU101 in patients with advanced solid tumors 
Article 
1998 60 0.93 
Multicenter phase II trial of interleukin-2, interferon-α, and 
13-cis- retinoic acid in patients with metastatic renal-cell 
carcinoma 
Article 
 
Table 5. The top 20 articles referenced by AHFS DI Essentials but attracting fewer citations 
than average for Antimicrobial Agents & Chemotherapy. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in 
journal 
website 
1997 0 0.00 
Pharmacokinetic interaction of megestrol acetate with 
zidovudine in human immunodeficiency virus-infected 
patients 
Article 
2000 5 0.48 
Bioavailability of once- and twice-daily regimens of 
didanosine in human immunodeficiency virus-infected 
children 
Article 
1996 5 0.53 Penetration of ceftibuten into middle ear fluid Article 
2011 4 0.55 
Concentrations of tenofovir and emtricitabine in saliva: 
Implications for preexposure prophylaxis of oral HIV 
acquisition 
Article 
1996 6 0.58 
Lack of effect of concomitant zidovudine on rifabutin 
kinetics in patients with AIDS-related complex 
Article 
1996 6 0.58 
Penetration of ceftriaxone (1 or 2 grams intravenously) 
into mediastinal and cardiac tissues in humans 
Article 
1996 7 0.62 
Absence of effect of trimethoprim-sulfamethoxazole on 
pharmacokinetics of zidovudine in patients infected with 
human immunodeficiency virus 
Article 
2006 8 0.63 
Dose separation does not overcome the pharmacokinetic 
interaction between fosamprenavir and lopinavir/ritonavir 
Article 
 
1997 9 0.64 
Rifabutin absorption in the gut unaltered by concomitant 
administration of didanosine in AIDS patients 
Article 
1999 10 0.65 
A multiple drug interaction study of stavudine with agents 
for opportunistic infections in human immunodeficiency 
virus-infected patients 
Article 
2011 6 0.67 
Nelfinavir and its active metabolite, hydroxy-t-
butylamidenelfinavir (M8), are transferred in small 
quantities to breast milk and do not reach biologically 
significant concentrations in breast-feeding infants whose 
mothers are taking nelfinavir 
Article 
1996 9 0.68 
Investigation of bioequivalence and tolerability of 
intramuscular ceftriaxone injections by using 1% lidocaine, 
buffered lidocaine, and sterile water diluents 
Article 
2014 3 0.70 EUCAST testing of isavuconazole susceptibility in Article 
Aspergillus: Comparison of results for inoculum 
standardization using conidium counting versus optical 
density 
2014 3 0.70 
Avibactam and class C β -lactamases: Mechanism of 
inhibition, conservation of the binding pocket, and 
implications for resistance 
Article 
2011 7 0.71 
In vitro efficacy of antibiotics commonly used to treat 
human plague against intracellular Yersinia pestis 
Article 
2011 7 0.71 
Pharmacokinetic interaction study of ritonavir-boosted 
saquinavir in combination with rifabutin in healthy 
subjects 
Article 
1997 13 0.73 
Pharmacokinetic study of cefodizime and ceftriaxone in 
sera and bones of patients undergoing hip arthroplasty 
Article 
2002 13 0.73 
Penciclovir susceptibilities of herpes simplex virus isolates 
from patients using penciclovir cream for treatment of 
recurrent herpes labialis 
Article 
1997 14 0.75 
Effect of fluconazole on the steady-state pharmacokinetics 
of delavirdine in human immunodeficiency virus-positive 
patients 
Article 
2007 12 0.76 
Diminished ciprofloxacin-induced chondrotoxicity by 
supplementation with magnesium and vitamin E in 
immature rats 
Article 
 
The higher average citation impact of articles in or Journal of Clinical Oncology and 
Antimicrobial Agents & Chemotherapy that are referenced by AHFS DI Essentials could be 
due to changes in classification practices in the journals over time or miss-classifications for 
a single issue, but this can be checked for by monitoring the results over time. Since the 
citation impact of articles referenced in AHFS DI Essentials is above the world average in 
every year (Figures 1 and 2), it is clear that isolated misclassifications or changes over time 
cannot explain the impact difference. To further check this, the smallest set of world articles 
from a single year was investigated in more detail, the 204 articles from 2015 in 
Antimicrobial Agents & Chemotherapy. All of these were correctly classified as articles, 
confirming that misclassifications are not a problem for this journal. The shortest article had 
only two pages (In vitro susceptibility testing of eravacycline is unaffected by medium age 
and nonstandard assay parameters) but these are labelled in the same way as long form 
articles and are clearly genuine research articles. This journal allows authors to submit short 
articles, but both are given equally rigorous reviewing and so it seems reasonable to regard 
them as equivalent, “The Short-Form format is intended for the presentation of brief 
observations that do not warrant full-length papers. Submit Short-Form papers in the same 
way as full-length papers. They receive the same review, they are not published more 
rapidly than full-length papers, and they are not considered preliminary communications.” 
(http://aac.asm.org/site/misc/journal-ita_org.xhtml#05). Nevertheless, longer articles tend 
to be slightly more cited (Pearson correlation 0.220 between page length and the natural 
log of citation counts plus one) and so it is possible that they are more valuable overall. This 
cannot explain the AHFS DI Essentials references advantage, however, since in 2015 they 
cite papers with average length 5.2 pages, whereas the journal average for the year was 6.3. 
Thus, the finding for Antimicrobial Agents & Chemotherapy in 2015 is not due to different 
article types (because there aren’t any) or lengths (because AHFS DI Essentials references 
cite shorter papers but longer papers in the journal tend to be more cited).  
  
Figure 1. MNLCS values for articles referenced by AHFS DI Essentials in the Journal of Clinical 
Oncology by year, together with 95% confidence intervals. Values above 1 indicate citation 
impact that is above the world average for the journal. 
 
 
Figure 2. MNLCS values for articles referenced by AHFS DI Essentials in the Antimicrobial 
Agents & Chemotherapy by year, together with 95% confidence intervals. Values above 1 
indicate citation impact that is above the world average for the journal. 
Discussion 
There are different possible reasons why articles referenced in AHFS DI Essentials tend to be 
more cited than average for the publishing general or specialist journal. For nine of the 
eleven examined journals, the reason is at least partly technical: submissions other than 
articles are classified as articles within Scopus, deflating the average citation count of all 
articles for the journal and therefore inflating the normalised citation count of genuine 
articles. A similar phenomenon has previously been observed for entire Scopus categories, 
with publications in trade journals classified as academic articles (Thelwall, 2016b). 
For at least two journals in which articles referenced in AHFS DI Essentials are 
genuinely more highly cited than average, there are several possible explanations. Drug-
specific research may be more citable than other medical research. This would explain the 
higher citation rates for general medical journals but not for specialist journals like 
Antimicrobial Agents & Chemotherapy (and Drugs). A second possibility is that being 
mentioned by AHFS DI Essentials gives an article publicity and helps it to generate additional 
citations. Conversely, more highly cited articles may be more likely to be selected by AHFS 
DI Essentials since they are more well-known for practical clinical studies. Both of these 
seem likely to be true to some extent. Unfortunately, it is not possible to separate these 
awareness reasons from the possibility that AHFS DI Essentials references are more useful 
than typical articles from the publishing journal.  
 The higher citation rates of AHFS DI Essentials references is unsurprising given similar 
evidence from a source of clinical guidelines (Thelwall & Maflahi, 2016) and clinical trials 
(Thelwall & Kousha, 2016). Since basic medical research seems to be more citable than 
clinical research (Narin, Pinski, & Gee, 1976) it may be that successful applied (clinical) 
research tends to be more highly cited than average in medicine. This may occur, for 
example, because research with practical medical applications (e.g., identifying side-effects 
or the effects of drugs on breastfeeding or pregnancy) is likely to trigger replication studies 
as well as follow-up research to check the findings in other contexts, for other diseases and 
with combinations of drugs. Moreover, other researchers may be inspired to take a similar 
approach to tackle a related problem. In contrast, it seems possible that more applied 
research in other areas tends to lead to a specific useful product or idea that is put into 
practice (e.g., in education) without generating follow-up research. 
 The apparent trend for higher MNLCS values for more recent years (Figures 1 and 2) 
does not have a clear explanation. Perhaps the most recent additions to AHFS DI Essentials 
references tend to be articles that more obviously have higher value than articles that have 
become accepted after a longer period of time. 
A limitation of this study is that citations in drug guides should not be taken as 
definitive evidence of applied medical research value. Even official government sources can 
use incorrect inadequate references and in any case may (and probably should) reference 
high quality systematic reviews, when available, instead of primary sources (Jefferson, Di 
Pietrantonj, Debalini, Rivetti, & Demicheli, 2009a). Moreover, although references in drug 
guides seem intuitively likely to have informed the advice, no study has definitively proven 
this and the choice of references may be influenced by national and other biases. Another 
limitation is that not all articles not cited by AHFS were checked for accurate Scopus 
classifications as articles. This would be time consuming to do and so only one year was 
checked (2015 in Antimicrobial Agents & Chemotherapy - see above) to confirm that not all 
of the results could be the result of misclassifications (or differing paper lengths). 
Conclusions 
The methods show that it is practical to extract AHFS DI Essentials references as evidence of 
the applied value of medical research. Since these articles tend to be more highly cited than 
average for the publishing journal, their extra value may already be recognised by their 
traditional academic citations, however. Thus, researchers that are concerned with their 
own citation counts should not be discouraged from attempting to run useful clinical 
studies. 
For individual researchers, an additional practical use of AHFS DI Essentials 
references is to support a clinical impact (e.g., informing practice, side-effects). At the time 
of writing, the simplest way to identify such references would be to run a site-specific 
Google search for the author’s last name of the form [name] 
site:drugs.com/monograph, such as Anakwenze 
site:drugs.com/monograph. For systematically gathering information for research 
evaluation exercises then the crawling methods discussed above can be used. 
 A corollary to the analysis in this study is that those using field normalised citation 
counts from Scopus for medical areas are likely to get inflated values due to the 
misclassification of non-articles as articles. This is likely to have affected the UK REF2014, for 
example. 
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Appendix 
This appendix includes article types for articles cited in AHFS DI Essentials but with low 
Scopus citation counts, relative to the field and year of publication. Each table reports one 
of the seven journals not discussed in the main body of the article (Tables A1-A7). 
 
Table A1. All articles referenced by AHFS DI Essentials but attracting fewer citations than 
average for New England Journal of Medicine. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in 
journal 
website 
2008 35 0.75 Urinary stress incontinence in women 
Clinical 
Practice 
2009 50 0.83 Activated protein C for sepsis 
Clinical 
therapeutics  
2012 35 0.84 
Topical 0.5% ivermectin lotion for treatment of head 
lice 
Article 
 
2005 66 0.87 Acne  
Clinical 
Practice  
2002 84 0.88 Head lice 
Clinical 
Practice  
2009 66 0.89 Fungal nail disease 
Clinical 
Practice 
2006 79 0.93 
Single-dose azithromycin for the treatment of 
cholera in adults 
Article 
2009 82 0.93 
Antivenom for critically ill children with 
neurotoxicity from scorpion stings 
Article 
2002 131 0.97 
Tissue plasminogen activator in cardiac arrest with 
pulseless electrical activity 
Article 
1997 43 0.97 
Cost effectiveness of oral as compared with 
intravenous antibiotic therapy for patients with 
early lyme disease or lyme arthritis 
Special 
Report 
2010 85 0.98 Retinal-vein occlusion 
Clinical 
Practice 
2003 165 1.00 Prolactinoma 
Clinical 
Practice 
 
The specialist journal Circulation has classification problems because some (three) of the 
articles in this journal are not standard journal articles. Several have the now discontinued 
subtype, Clinical Investigation and Reports, which probably equivalent to a traditional 
journal article (Table A2). Similar classification errors also occurred in some of the remaining 
articles in this journal. 
 
  
Table A2. All articles referenced by AHFS DI Essentials but attracting fewer citations than 
average for Circulation. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in journal 
website 
2012 13 0.76 
Guided antithrombotic therapy: Current 
status and future research direction: Report 
on a national heart, lung and blood institute 
working group 
Special Report             
2001 41 0.83 
Prognostic significance of thrombocytopenia 
during hirudin and heparin therapy in acute 
coronary syndrome without ST elevation: 
Organization to assess strategies for 
ischemic syndromes (OASIS-2) study 
Clinical 
Investigation and 
Reports 
2000 44 0.86 
Survival outcomes 1 year after reperfusion 
therapy with either alteplase or reteplase for 
acute myocardial infarction: Results from the 
global utilization of streptokinase and t-PA 
for occluded coronary arteries (GUSTO) III 
trial 
Clinical 
Investigation and 
Reports 
2005 51 0.88 
The use of nonsteroidal anti-inflammatory 
drugs (NSAIDs): A Science Advisory from the 
American Heart Association 
AHA Science 
Advisory 
1999 57 0.92 
Stroke in patients with acute coronary 
syndromes: Incidence and outcomes in the 
platelet glycoprotein IIb/IIIa in unstable 
angina: Receptor suppression using integrilin 
therapy (PURSUIT) trial 
Clinical 
Investigation and 
Reports 
2003 85 0.98 
The use of nonsteroidal anti-inflammatory 
drugs (NSAIDs): A Science Advisory from the 
American Heart Association 
AHA Scientific 
Statements 
 
  
Table A3. All articles referenced by AHFS DI Essentials but attracting fewer citations than 
average for BMJ. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in 
journal 
website 
1999 3 0.35 
Drug points: Fatal erythroderma associated with 
pentostatin 
Article 
1996 18 0.77 
Addison's disease presenting as reduced insulin 
requirement in insulin dependent diabetes 
Education 
and 
Debate 
1997 23 0.81 
Simultaneous immunisation with influenza vaccine and 
pneumococcal polysaccharide vaccine in patients with 
chronic respiratory disease 
Article 
2002 28 0.81 
Metabolic decompensation in pump users due to lispro 
insulin precipitation 
Article 
2001 35 0.87 
Drug points: Cholestatic hepatitis in association with 
celecoxib 
 
2008 29 0.88 
Hypersensitivity reactions to human papillomavirus 
vaccine in Australian schoolgirls: Retrospective cohort 
study 
Article 
1997 38 0.93 
Acute angle closure glaucoma associated with 
paroxetine 
Article 
 
  
Table A4. Top 20 articles referenced by AHFS DI Essentials but attracting fewer citations 
than average for Clinical Infectious Diseases. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in journal 
website 
1996 2 0.37 
Early initiation of antiretroviral therapy for infection 
with human immunodeficiency virus: Considerations 
in 1996 
Article 
2009 3 0.38 
Outcomes among inmates treated for 
coccidioidomycosis at a correctional institution during 
a community outbreak, kern county, California, 2004 
Article 
1997 5 0.56 
Measurement of human immunodeficiency virus 
(HIV) type 1 RNA load distinguishes progressive 
infection from nonprogressive HIV-1 infection in men 
and women 
Brief report 
1997 5 0.56 Cerebral relapse of sarcoidlike Whipple's disease Article 
1998 8 0.69 
Anaphylaxis upon switching lipid-containing 
amphotericin B formulations 
Brief report 
1996 7 0.69 
Fluconazole-resistant Candida parapsilosis fungemia 
in a patient with AIDS 
Brief report 
1997 9 0.72 
Cardiac arrhythmias associated with coadministration 
of azole compounds and cisapride [4] (multiple 
letters) 
Correspondence 
1999 10 0.75 
Hydroxyurea toxicity in human immunodeficiency 
virus-positive patients 
Brief report 
2009 15 0.76 Cefepime therapy and all-cause mortality View point 
1997 11 0.78 
Recurrent iritis after intravenous administration of 
cidofovir 
Brief report 
2000 17 0.81 
Rhodococcus equi nosocomial meningitis cured by 
levofloxacin and shunt removal 
Brief report 
1999 13 0.82 
Hydroxyurea-induced hepatitis in human 
immunodeficiency virus-positive patients 
Brief report 
1999 13 0.82 
Primary lamivudine resistance in acute/early human 
immunodeficiency virus infection 
Brief report 
2001 20 0.85 
Failure of treatment for chronic Mycobacterium 
abscessus meningitis despite adequate clarithromycin 
levels in cerebrospinal fluid 
Brief report 
1997 15 0.87 
A fluconazole/amitriptyline drug interaction in three 
male adults 
Brief report 
2001 22 0.88 
Cerebrospinal fluid penetration of levofloxacin in 
patients with spontaneous acute bacterial meningitis 
Brief report 
2010 19 0.89 
Two cases of daptomycin-induced eosinophilic 
pneumonia and chronic pneumonitis 
Brief report 
1998 17 0.91 
Successful treatment of primary Actinomyces viscosus 
endocarditis with third-generation cephalosporins 
Brief report 
2001 25 0.91 
Ivermectin treatment of a traveler who returned from 
Peru with cutaneous gnathostomiasis. 
Brief report 
2000 25 0.92 
Cerebrospinal fluid penetration of high doses of 
intravenous ciprofloxacin in meningitis 
Article 
 
Table A5. All articles referenced by AHFS DI Essentials but attracting fewer citations than 
average for Archives of Internal Medicine/JAMA Internal Medicine. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in 
journal 
website 
2001 6 0.48 
A randomized Multicenter Trial of Crotalinae polyvalent 
immune Fab (ovine) antivenom for the treatment for 
crotaline snakebite in the United States 
Article 
1998 22 0.76 A drug interaction between zafirlukast and theophylline 
Clinical 
Observation 
1997 24 0.79 
Fluconazole as prophylaxis against fungal infection in 
patients with advanced HIV infection 
Article  
1996 25 0.81 Severe hyponatremia during therapy with fluoxetine Article 
2005 36 0.82 
Bortezomib-induced severe hepatitis in multiple 
myeloma: A case report 
Clinical 
Observation 
1996 28 0.84 
Clinical ergotism with lingual ischemia induced by 
clarithromycin-ergotamine interaction 
Article 
2005 57 0.93 
Selective cyclooxygenase-2 inhibition and cardiovascular 
effects: An observational study of a medicaid population 
Article 
2000 64 0.94 
Safety and efficacy of meloxicam in the treatment of 
osteoarthritis: A 12-week, double-blind, multiple-dose, 
placebo-controlled trial 
Article 
 
Table A6. All articles referenced by AHFS DI Essentials but attracting fewer citations than 
average for Pediatrics. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in 
journal 
website 
1996 22 0.84 
Clinical and pathologic aspects of cardiomyopathy from 
ipecac administration in Munchausen's syndrome by 
proxy 
Article 
1996 32 0.94 
Combination therapy with stavudine and didanosine in 
children with advanced human immunodeficiency virus 
infection: Pharmacokinetic properties, safety, and 
immunologic and virologic effects 
Article 
1996 35 0.96 Use of diet history in the screening of iron deficiency Article 
1996 38 0.98 
Recurrent thrombocytopenic purpura after repeated 
measles-mumps-rubella vaccination 
Experience 
and 
Reason 
1996 40 0.99 
Methylene blue-induced phototoxicity: An unrecognized 
complication 
Article 
1997 44 0.99 
Needle length and injection technique for efficient 
intramuscular vaccine delivery in infants and children 
evaluated through an ultrasonographic determination of 
subcutaneous and muscle layer thickness 
Experience 
and 
Reason 
1999 15 0.71 
Assessment of medical personnel exposure to nitrogen 
oxides during inhaled nitric oxide treatment of neonatal 
and pediatric patients 
Article 
1999 34 0.91 
Thalidomide responsiveness in an infant with Behcet's 
syndrome 
Experience 
and 
Reason 
1999 40 0.95 
Prevention of poliomyelitis: Recommendations for use 
of only inactivated poliovirus vaccine for routine 
immunization 
Guideline 
2000 15 0.69 
Fomepizole treatment of ethylene glycol poisoning in an 
infant 
Case 
Report 
2001 30 0.83 
Severe ethylene glycol ingestion treated without 
hemodialysis 
Case 
Reports 
2001 61 1.00 
Insulin lispro lowers postprandial glucose in prepubertal 
children with diabetes 
Article 
2002 21 0.74 
Interchangeability of 2 diphtheria-tetanus-acellular 
pertussis vaccines in infancy 
Clinical 
Trial 
2002 45 0.92 
Crotaline Fab antivenom for the treatment of children 
with rattlesnake envenomation 
Article 
2002 53 0.96 
Terbinafine in the treatment of Trichophyton tinea 
capitis: A randomized, double-blind, parallel-group, 
duration-finding study 
Article 
2004 19 0.74 
Risk Factors for Emesis after Therapeutic Use of 
Activated Charcoal in Acutely Poisoned Children 
Article 
2007 33 0.97 
Infant botulism: A 30-year experience spanning the 
introduction of botulism immune globulin intravenous in 
the intensive care unit at Childrens Hospital Los Angeles 
Article 
2008 24 0.87 
Coadministration of RIX4414 oral human rotavirus 
vaccine does not impact the immune response to 
antigens contained in routine infant vaccines in the 
united states 
Article 
2008 26 0.89 
Safety and immunogenicity of concureent 
administration of live attenuated influenza vaccine with 
measles-mumps-rubella and varicella vaccines to infants 
12 to 15 months of age 
Article 
 
  
Table A7. All articles referenced by AHFS DI Essentials but attracting fewer citations than 
average for Drugs. 
Year 
Scopus 
citations 
Norm. 
cit. 
Article Type in 
journal 
website 
1997 6 0.58 
Ancillary benefits of Mycobacterium avium-
intracellulare complex prophylaxis with 
clarithromycin in HIV-infected patients 
Article 
2014 3 0.59 Suvorexant: First global approval Article 
2013 4 0.62 
Crofelemer: A review of its use in the management 
of non-infectious diarrhoea in adult patients with 
HIV/AIDS on antiretroviral therapy 
Article 
2012 5 0.68 Aclidinium: In chronic obstructive pulmonary disease 
Adis Drug 
Profile 
2015 2 0.69 Evolocumab: First Global Approval 
Adis Insight 
Report  
1999 15 0.79 
Isosorbide 5-mononitrate. A review of a sustained-
release formulation (Imdur®) in stable angina 
pectoris 
Adis Drug 
Evaluation 
1998 19 0.83 
Recent antiplatelet drug trials in the acute coronary 
syndromes. Clinical interpretation of PRISM, PRISM-
PLUS, PARAGON A and PURSUIT 
Leading 
Article 
1999 18 0.84 
Clinical efficacy of metformin against insulin 
resistance parameters sinking the iceberg 
Review 
Article 
2001 24 0.85 Fulvestrant 
Adis New 
Drug Profile 
1998 22 0.87 
Topotecan: A review of its potential in advanced 
ovarian cancer 
Adis Drug 
Evaluation 
1996 19 0.87 
Pharmacological Treatment of Psychiatric Disorders 
in Children and Adolescents: Focus on Guidelines for 
the Primary Care Practitioner 
Article 
 
2015 3 0.88 Alirocumab: First Global Approval 
Adis Insight 
Report 
2014 7 0.89 Vorapaxar: First global approval 
R&D Insight 
Report 
2001 28 0.89 Thalidomide in gastrointestinal disorders 
Therapy in 
Practice 
1996 22 0.91 Head and Neck Cancer: Guidelines for Chemotherapy 
Disease 
Management 
1997 24 0.96 
Current recommendations for the management of 
bladder cancer: Drug therapy 
Disease 
Management 
2001 40 0.98 Desloratadine 
Adis New 
Drug Profile 
1998 35 0.99 Management of malignant pleural effusions 
Disease 
Management 
 
